Antibody-dependent enhancement (ADE) has long been a thorn in the side of dengue vaccine developers. In the Aug. 14, 2018, issue of Cell Reports, a team from the University of Texas Medical Branch showed that ADE occurred with human antibodies to the Ebola virus as well, but it could be prevented by engineering antibodies to prevent their interaction with immune cells.